Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice

Montoro, Maria Julia; Pomares, Helena; Coll, Rosa; Bernal del Castillo, Teresa; Tormo, Mar; Jiménez, Ana; Brunet, Salut; Casaño, Javier; Oiartzabal, Itziar; Díez-Campelo, María; Ramos, Fernando; Romero, Rafael; Salido-Fiérrez, Eduardo; Pedro Olive, Carme; Bargay, Joan; Muñoz-Novas, Carolina; López, Rocío; Rafel, Montserrat; Valcárcel, David; ERASME study group

Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice

Mostra el registre complet Registre parcial de l'ítem

dc.contributor.author Montoro, Maria Julia
dc.contributor.author Pomares, Helena
dc.contributor.author Coll, Rosa
dc.contributor.author Bernal del Castillo, Teresa
dc.contributor.author Tormo, Mar
dc.contributor.author Jiménez, Ana
dc.contributor.author Brunet, Salut
dc.contributor.author Casaño, Javier
dc.contributor.author Oiartzabal, Itziar
dc.contributor.author Díez-Campelo, María
dc.contributor.author Ramos, Fernando
dc.contributor.author Romero, Rafael
dc.contributor.author Salido-Fiérrez, Eduardo
dc.contributor.author Pedro Olive, Carme
dc.contributor.author Bargay, Joan
dc.contributor.author Muñoz-Novas, Carolina
dc.contributor.author López, Rocío
dc.contributor.author Rafel, Montserrat
dc.contributor.author Valcárcel, David
dc.contributor.author ERASME study group
dc.date.accessioned 2023-04-18T06:25:47Z
dc.date.available 2023-04-18T06:25:47Z
dc.date.issued 2023
dc.description.abstract Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases without a care standard and show variability in treatment outcomes. This Spanish, observational, prospective study ERASME (CEL-SMD-2012-01) assessed the evolution of newly diagnosed and treatment-naïve high-risk MDS patients (according to IPPS-R). 204 patients were included: median age 73.0 years, 54.4% males, 69.6% 0-1 ECOG, and 94.6% with comorbidities. Active treatment was the most common strategy (52.0%) vs. stem cell transplantation (25.5%) and supportive care/watchful-waiting (22.5%). Overall (median) event-free survival was 7.9 months (9.1, 8.3, and 5.3); progression-free survival: 10.1 months (12.9, 12.8, and 4.3); and overall survival: 13.8 months (15.4, 14.9; 8.4), respectively, with significant differences among groups. Adverse events (AEs) of ≥3 grade were reported in 72.6% of patients; serious AEs reported in 60.6%. 33.1% of patients died due to AEs. Three patients developed second primary malignant neoplasms (median: 8.2 months). Our study showed better outcomes in patients receiving active therapy early after diagnosis.
dc.format.mimetype application/pdf
dc.identifier.citation Montoro MJ, Pomares H, Coll R, Bernal Del Castillo T, Tormo M, Jiménez A, Brunet S, Casaño J, Oiartzabal I, Díez-Campelo M, Ramos F, Romero R, Salido-Fiérrez E, Pedro C, Bargay J, Muñoz-Novas C, López R, Rafel M, Valcárcel D; ERASME study group. Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice. Leuk Lymphoma. 2023 Mar;64(3):679-90. DOI: 10.1080/10428194.2022.215460
dc.identifier.doi http://dx.doi.org/10.1080/10428194.2022.215460
dc.identifier.issn 1042-8194
dc.identifier.uri http://hdl.handle.net/10230/56484
dc.language.iso eng
dc.publisher Taylor & Francis
dc.relation.ispartof Leuk Lymphoma. 2023 Mar;64(3):679-90
dc.rights © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.keyword Clinical practice
dc.subject.keyword High-risk
dc.subject.keyword Myelodysplastic syndrome
dc.subject.keyword Real-world evidence
dc.subject.keyword Treatment
dc.title Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice
dc.type info:eu-repo/semantics/article
dc.type.version info:eu-repo/semantics/publishedVersion

Col·leccions

Articles (Hospital del Mar Research Institute)